Business Context and Reporting Period
This Form 8-K is a current report filed by Eyenovia, Inc. (not Hyperion Defi, Inc.) on February 13, 2019. The filing discloses the execution of new executive employment agreements and related compensation arrangements effective February 15, 2019. The company is incorporated in Delaware and identifies as an Emerging Growth Company.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- CEO/CMO (Tsontcho Ianchulev): Base salary of at least $450,000 per year.
- CFO (John Gandolfo): Base salary of at least $366,000 per year.
- VP Clinical Operations (Jennifer Clasby): Base salary of at least $279,000 per year.
- VP R&D and Manufacturing (Luke Clauson): Base salary of at least $307,000 per year.
- VP Marketing (Michael Rowe): Base salary of at least $275,000 per year.
Material Changes and Compensation Terms
The company entered into employment agreements with five key executives. Key terms include:
- Annual Bonuses: Eligible based on pre-established individual and company objectives.
- Equity: Eligible for grants under the 2018 Omnibus Stock Incentive Plan.
- Standard Severance: Upon termination without Cause or Involuntary Termination, executives receive 3 months of base salary and 3 months of COBRA health insurance reimbursement.
- Change in Control Severance: If termination occurs within 12 months of a Corporate Transaction, severance increases to 12 months of base salary and 12 months of COBRA reimbursement.
- Non-Competition: Executives are subject to non-compete and non-solicitation restrictions for 3 months post-termination (standard) or 12 months post-termination (following a Corporate Transaction).
Outlook, Risks, and Unusual Items
Unusual Item: On February 13, 2019, the Board of Directors approved the acceleration and immediate vesting of 124,210 non-qualified stock options originally granted to CEO Tsontcho Ianchulev on July 24, 2018.
Risks/Contingencies: The filing notes that severance payments are contingent upon the executive signing a full release of all claims against the company.
Investor Verification Checklist
- Verify the total number of outstanding stock options following the acceleration of 124,210 options for Dr. Ianchulev.
- Review the specific performance metrics for the annual cash bonuses, which are determined by the Board or Compensation Committee.
- Confirm the definitions of "Cause," "Involuntary Termination," and "Corporate Transaction" in the attached exhibits (10.16 through 10.21) to understand severance triggers.
- Assess the impact of the new base salary commitments on the company's future operating expenses.